

Please delete the 8 pages of DRAWINGS in the application as filed, and substitute therefor the 7 pages of replacement drawings enclosed herewith.

In the SPECIFICATION:

Please delete the section "Priority Claim" on page 1, and substitute therefor:

-- REFERENCE TO RELATED APPLICATIONS

A¹
This application is a continuation of International Application PCT/US00/03104, designating the U.S., filed April 10, 2000, pending, which is a continuation-in-part of U.S. Patent Application 09/244,438. These two priority applications are hereby incorporated herein by reference in their entirety. --

Please delete the description of Figure 4 in the "Brief Description of the Drawings", page 4, lines 3-13, and substitute therefor:

-- Figure 4 is a half tone reproduction of cell lines photographed 7 days after infection with oncolytic virus. Top row: uninfected cells (negative control). Middle row: cells infected with oncolytic adenovirus, in which replication gene E1a is operably linked to the hTERT promoter. Bottom row: cells infected with adenovirus in which E1a is operably linked to the CMV promoter (positive control).

A²
The cells tested were as follows: Figure 4(A): BJ (foreskin fibroblast); IMR-90 (lung fibroblast); WI-38 (lung fibroblast); cells of non-malignant origin. Figure 4(B): DAOY (medulloblastoma); HeLa (cervical carcinoma); HT1080 (fibrosarcoma). Not shown: A549 (lung carcinoma) AsPC-1 and BxPC-3: (adenocarcinoma, pancreas). The results show that the hTERT-regulated oncolytic virus specifically lyses cancer cells, in preference to cell lines that don't express telomerase reverse transcriptase at a substantial level. This is in contrast to oncolytic virus regulated by a constitutive promoter like CMV promoter, which lyses cells non-specifically. --